Concepedia

Andrew Worden

AW

Statistics

Publications

8

Citations

850

H-Index

8

Active since

2018

Affiliations

Lentigen Technology (United States)(Current)

Case Western Reserve University

University of Washington

University Hospitals Seidman Cancer Center

Medical College of Wisconsin

Andrew Worden is an author at Lentigen Technology (United States) specializing in oncology, radiation oncology, and immunology.

ORCID

Top concepts

Publications per year

2018–2021

8

Publications

8

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

Nirav N. Shah, Bryon D. Johnson, Dina Schneider et al. · Nature Medicine · 2020 · 439 citations

, , +7

Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model

Kim Anthony-Gonda, Ariola Bardhi, Alex Ray et al. · Science Translational Medicine · 2019 · 152 citations · Full text

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma

Zachary Jackson, Anne Roe, Ashish Sharma et al. · Frontiers in Immunology · 2020 · 93 citations · Full text

Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients

Michael Maschan, Paolo F. Caimi, Jane Reese‐Koc et al. · Nature Communications · 2021 · 66 citations · Full text

Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.

Nirav N. Shah, Fenlu Zhu, Dina Schneider et al. · Journal of Clinical Oncology · 2019 · 42 citations

, , +18

1–5 of 8